BBIO PE Ratio & Valuation, Is BBIO Overvalued

Historical Valuation

BridgeBio Pharma Inc (BBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 20.57 is considered Fairly compared with the five-year average of -9.51. The fair price of BridgeBio Pharma Inc (BBIO) is between 40.91 to 465.35 according to relative valuation method.

Relative Value

Fair Zone

40.91-465.35

Current Price：71.03

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is BridgeBio Pharma Inc (BBIO) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

BridgeBio Pharma Inc (BBIO) has a current Price-to-Book (P/B) ratio of -7.80. Compared to its 3-year average P/B ratio of -4.37, the current P/B ratio is approximately 78.40% higher. Relative to its 5-year average P/B ratio of -4.15, the current P/B ratio is about 87.90% higher. BridgeBio Pharma Inc (BBIO) has a Forward Free Cash Flow (FCF) yield of approximately -3.89%. Compared to its 3-year average FCF yield of -9.52%, the current FCF yield is approximately -59.17% lower. Relative to its 5-year average FCF yield of -15.21%, the current FCF yield is about -74.45% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for BBIO competitors is 34.31, providing a benchmark for relative valuation. BridgeBio Pharma Inc Corp (BBIO.O) exhibits a P/S ratio of 20.57, which is -40.03% above the industry average. Given its robust revenue growth of 2521.18%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of BBIO increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of BBIO in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is BBIO currently overvalued or undervalued?

What is BridgeBio Pharma Inc (BBIO) fair value?

BBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of BridgeBio Pharma Inc (BBIO) is between 40.91 to 465.35 according to relative valuation method.

How does BBIO's valuation metrics compare to the industry average?

The average P/S ratio for BBIO's competitors is 34.31, providing a benchmark for relative valuation. BridgeBio Pharma Inc Corp (BBIO) exhibits a P/S ratio of 20.57, which is -40.03% above the industry average. Given its robust revenue growth of 2521.18%, this premium appears sustainable.

What is the current P/B ratio for BridgeBio Pharma Inc (BBIO) as of Mar 16 2026?

As of Mar 16 2026, BridgeBio Pharma Inc (BBIO) has a P/B ratio of -7.80. This indicates that the market values BBIO at -7.80 times its book value.

What is the current FCF Yield for BridgeBio Pharma Inc (BBIO) as of Mar 16 2026?

As of Mar 16 2026, BridgeBio Pharma Inc (BBIO) has a FCF Yield of -3.89%. This means that for every dollar of BridgeBio Pharma Inc's market capitalization, the company generates -3.89 cents in free cash flow.

What is the current Forward P/E ratio for BridgeBio Pharma Inc (BBIO) as of Mar 16 2026?

As of Mar 16 2026, BridgeBio Pharma Inc (BBIO) has a Forward P/E ratio of -33.67. This means the market is willing to pay $-33.67 for every dollar of BridgeBio Pharma Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for BridgeBio Pharma Inc (BBIO) as of Mar 16 2026?

As of Mar 16 2026, BridgeBio Pharma Inc (BBIO) has a Forward P/S ratio of 20.57. This means the market is valuing BBIO at $20.57 for every dollar of expected revenue over the next 12 months.

BBIO Valuation